Evidence map›Paper›PMID 36466856›Full record

ArticleFrontiers in immunology2022

Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients.

Shirin Emtenani, Maike M Holtsche, Richard Stahlkopf, Daniel L Seiler, Timothy Burn, Huiqing Liu, Melissa Parker, Kaan Yilmaz, Hasan O Dikmen, Markus Huber Lang and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Shirin EmtenaniLübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.
Maike M HoltscheDepartment of Dermatology, Allergy, and Venereology, University of Lübeck, Lübeck, Germany.
Richard StahlkopfLübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.
Daniel L SeilerInstitute for Systemic Inflammation Research (ISEF), University of Lübeck, Lübeck, Germany.
Timothy BurnIncyte Research Institute, Wilmington, DE, United States.
Huiqing LiuIncyte Research Institute, Wilmington, DE, United States.
Melissa ParkerIncyte Research Institute, Wilmington, DE, United States.
Kaan YilmazDepartment of Dermatology, Allergy, and Venereology, University of Lübeck, Lübeck, Germany.
Hasan O DikmenDepartment of Dermatology, Allergy, and Venereology, University of Lübeck, Lübeck, Germany.
Markus Huber LangInstitute of Experimental Trauma-Immunology, University Hospital of Ulm, Ulm, Germany.
Christian D SadikDepartment of Dermatology, Allergy, and Venereology, University of Lübeck, Lübeck, Germany.
Christian M KarstenInstitute for Systemic Inflammation Research (ISEF), University of Lübeck, Lübeck, Germany.
Nina van BeekDepartment of Dermatology, Allergy, and Venereology, University of Lübeck, Lübeck, Germany.
Ralf J LudwigLübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.
Jörg KöhlInstitute for Systemic Inflammation Research (ISEF), University of Lübeck, Lübeck, Germany.
Enno SchmidtLübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.
University of Lübeck · DEIncyte (United States) · USCincinnati Children's Hospital Medical Center · USUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bullous pemphigoid (BP), the by far most frequent autoimmune subepidermal blistering disorder (AIBD), is characterized by the deposition of autoantibodies against BP180 (type XVII collagen; Col17) and BP230 as well as complement components at the dermal-epidermal junction (DEJ). The mechanisms of complement activation in BP patients, including the generation of C5a and regulation of its two cognate C5aRs, i.e., C5aR1 and C5aR2, are incompletely understood. In this study, transcriptome analysis of perilesional and non-lesional skin biopsies of BP patients compared to site-, age-, and sex-matched controls showed an upregulated expression of

Indexed as

Pemphigoid, BullousSkin DiseasesAnimalsBiopsyHumansLeukocyte CountMiceReceptor, Anaphylatoxin C5aSkinC5ar1 protein, mouseC5ar2 protein, mouseReceptor, Anaphylatoxin C5aautoimmune blistering diseasebullous pemphigoidC5a/C5aR axiscomplement activationcomplement component 5a receptor (C5aR) 1/2neutrophils

Identifiers

PMID36466856
PMCPMC9716273
OpenAlexW4309462636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.